×

Nuvilex Subsidiary, Austrianova Singapore, Publishes Advantages of its Encapsulated Cell Therapy for the Cell-Based Therapeutic Treatment of Diabetes

Nuvilex, Inc. Logo

SILVER SPRING, Md., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today its subsidiary Austrianova Singapore (ASPL) has published a new manuscript that describes the use of the Company's proprietary cell encapsulation technology for studies designed to create a cell based therapeutic treatment for diabetes.

The publication in the Wiener Medizinische Wochenschrift Skriptum, entitled "Cell encapsulation for the treatment of diabetes" was co-authored with Dr. Eva Brandtner, former ASPL Chief Scientific Officer who is presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria. The manuscript outlines the advantages of using cellulose sulfate for the encapsulation of cells for treatment of diabetes. The article accompanied an invited presentation on the same topic at the Diabetes Meeting in Salzburg, Austria also given by Dr. Brandtner.

ASPL and VIVIT have planned and are working closely together to advance and develop the diabetes treatment using encapsulated cells capable of expressing insulin after they detect the presence of glucose. Ultimately, the aim is to place insulin-secreting cells encapsulated in cellulose sulphate in patients with diabetes to replace the patient's own cells that no longer secrete insulin in response to elevated levels of glucose. As a result, the encapsulated cells thereby replace the normal pancreatic cells and enable the body to function normally, preventing exposure to the debilitating effects of high levels of glucose in the body.

The CEO of ASPL, Dr. Brian Salmons, said, "We are very happy to have been able to release our data through this publication from our testing of the encapsulated live cell treatment potential for diabetes. Being able to continue our work with VIVIT and Dr. Eva Brandtner, will greatly enhance our ability to develop and advance diabetes treatments."

The President and CEO of Nuvilex, Dr. Robert Ryan, stated "Our commitment to create valuable patient treatments through the proprietary cell encapsulation developed over so many years by ASPL, including treatments for diabetes, has become stronger over the past year. The important advances made have been through the funding provided by Nuvilex this past year and will prove valuable in the coming years. Clearly the ability to treat patients with this disease is a major driving force for our companies. From a market perspective, the World Health Organization has shown that the economic benefits will be substantial as the costs of diabetes are presently estimated to be over $350 Billion dollars spent annually per year worldwide."

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Important advances are moving Nuvilex and Austrianova Singapore forward. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. We hope to bring some of these to light very soon. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 mmolinarofc@aol.com

Source:Nuvilex, Inc.